Meet Kevin Pricing Power ETF News - PP | Aktien Amerikanische Börse

The Meet Kevin Pricing Power ETF (PP) to Close

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tidal Financial Group and Plato’s Philosophy LLC announce the...

- Statement of Beneficial Ownership (SC 13D)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Pipex...

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-KSB/A AMENDMENT No. 1 ANNUAL REPORT...

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ý...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13...

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D INFORMATION STATEMENT PURSUANT TO RULES 13D-1 AND...

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to...

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ...

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE...

Pipex Pharmaceuticals, Inc. - Proxy Statement (definitive) (DEF 14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY...

Pipex Pharmaceuticals, Inc. - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY...

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Meet Kevin Pricing Power ETF (PP)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

PP Nachrichten

The Meet Kevin Pricing Power ETF (PP) to Close

- Statement of Beneficial Ownership (SC 13D)

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Proxy Statement (definitive) (DEF 14A)

Pipex Pharmaceuticals, Inc. - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

PP Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Meet Kevin Pricing Power ETF (PP) News

Meet Kevin Pricing Power ETF (PP)

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

PP Nachrichten

The Meet Kevin Pricing Power ETF (PP) to Close

- Statement of Beneficial Ownership (SC 13D)

Pipex Pharmaceuticals, Inc. - Amended Annual Report (Small Business Issuers) (10KSB/A)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Amended Statement of Beneficial Ownership (SC 13D/A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Quarterly Report (10-Q)

Pipex Pharmaceuticals, Inc. - Current report filing (8-K)

Pipex Pharmaceuticals, Inc. - Proxy Statement (definitive) (DEF 14A)

Pipex Pharmaceuticals, Inc. - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A)

Pipex Pharmaceuticals, Inc. - Statement of Changes in Beneficial Ownership (4)

PP Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen